

**ID: 131**

Area Clinica

**Orale**

Parole chiave: Sickle Cell Disease, Liver Disease

### **Liver damage in Sickle Cell Disease: relevance of early markers**

**Marta Bortolotti<sup>1</sup>, Roberta D'Ambrosio<sup>2</sup>, Mirella Fraquelli<sup>3</sup>, Pedrotti Patrizia<sup>4</sup>, Alessia Marcon<sup>1</sup>, Juri Alessandro Giannotta<sup>5</sup>, Maria Domenica Cappellini<sup>1</sup>, Giovanna Graziadei<sup>6</sup>**

<sup>1</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italia - Attività Diurne Malattie Rare Internistiche - Medicina Generale - Università degli Studi di Milano; <sup>2</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italia - Divisione di Gastroenterologia ed Epatologia; <sup>3</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italia - Divisione di Gastroenterologia ed Endoscopia; <sup>4</sup>ASST GOM Niguarda, Laboratorio di Risonanza Magnetica Cardiaca, Cardiologia; <sup>5</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italia - Divisione di Ematologia - Università degli Studi di Milano; <sup>6</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italia - Attività Diurne Malattie Rare Internistiche - Medicina Generale; [marta.bortolotti1@studenti.unimi.it](mailto:marta.bortolotti1@studenti.unimi.it)

Introduction. Liver damage is a severe complication in Sickle Cell Disease (SCD), so far, no effective approaches to prevent or treat it are available.

Aim. To identify early predictors of liver involvement.

Patients and methods. Seventeen Sickle Cell Anemia (SCA), 38 Sickle Cell Thalassemia (HbS- $\beta$ Thal) and 13 HbS/HbC patients with two Stiffness data (Transient Elastography TE) (T0 and T1), were evaluated (2007-2016). Clinical manifestations, therapy, laboratory tests, abdominal ultrasound (US) and Magnetic Resonance Imaging (MRI) T2\* were recorded

Results. AST, ALT, LDH were higher in SCA pts than in HbS- $\beta$ Thal and HbSC (ALT  $p < 0.0001$ ) and in HbS- $\beta$ Thal compared to HbSC (ALT  $p = 0.01$ ). GGT, ALP were higher in SCA than in HbS- $\beta$ Thal and HbSC (GGT  $p = 0.013$ ; ALP  $p = 0.006$ ), and without significance in HbS- $\beta$ Thal compared to HbSC (GGT  $p = 0.23$ ; ALP  $p = 0.44$ ). Liver synthesis indices were similar; none was HbsAg nor HCV-RNA positive. TE Stiffness was higher in SCA (KPa  $8.3 \pm 6.86$ ) than in HbSC pts (KPa  $5.33 \pm 2.15$ ;  $p = 0.014$ ) and in HbS- $\beta$ Thal (KPa  $6.17 \pm 2.58$ ) comparing SCA and HbSC pts ( $p = 0.2$ ). Liver Iron Concentration (LIC) was higher in HbS- $\beta$ Thal than in SCA and HbSC pts (HbS- $\beta$ Thal vs HbSC  $p = 0.0145$ ) and in SCA comparing HbSC ( $p = 0.018$ ). At univariate analysis GGT correlates with ferritin ( $p = 0.02$ ), TE ( $p = 0.002$ ), US ( $p = 0.107$ ) and LIC ( $p = 0.511$ ) in all SCD pts. A correlation between GGT and US liver echogenicity was in SCA and HbS- $\beta$ Thal pts; TE and US ( $p = 0.045$ ) correlated positively in all SCD pts. No differences were found in TE and MRI T2\* at T0 and T1. US showed statistic differences at T0 compared with T1 in HbS- $\beta$ Thal ( $p = 0.04$ ) and in HbSC pts ( $p = 0.001$ ), but not in SCA pts ( $p = 0.46$ ) probably because of higher Stiffness since T0. The 76.5% of SCA, 60.5% of HbS- $\beta$ Thal and 30.8% of HbSC pts had  $>1$  vaso-occlusive crisis (VOCs)/yr (SCA vs HbSC  $p = 0.02$ ; SCA vs HbS- $\beta$ Thal  $p = 0.36$ ; HbS- $\beta$ Thal vs HbSC  $p = 0.001$ ). Occasional transfusions ( $<4$  RBCs Units/yr) occurred in 88.2% of SCA, 84.2% of HbS- $\beta$ Thal and 61.5% of HbSC pts. The 58.8% of SCA, 65.8% of HbS- $\beta$ Thal and 15.4% of HbSC pts took HydroxyCarbamide and 23.5% of SCA, 23.7% of HbS- $\beta$ Thal and none of HbSC pts took iron-chelators.

At multivariate analysis sex (male), low HbF values, high ferritin values, more severe sickle genotype as predictors of liver involvement were found independent risk factors.

Conclusions. Function liver tests with US, TE and MRI T2\* taking into account sex, HbF, and SCD genotypes, are useful to early detect sickle hepatopathy.